Elicio Therapeutics, Inc.
NASDAQ:ELTXBiotechnology
Healthcare
$2.70 -18.90%
-$0.89 today
- Market cap
- $51.48M
- Beta
- 1.14
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$2.21
52W Low $2.66High $16.00
Volume 0.41M
Average 0.34M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$37.71M
FY 2025 · Annual
Net Income
-$39.57M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 28.31M | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.23M | 1.06M | 1.17M | 1.18M | 1.13M |
| Gross Profit | 27.08M | (1.06M) | (1.17M) | (1.18M) | (1.13M) |
| Gross Margin | 95.6% | — | — | — | — |
| Research & Development | 48.61M | 17.05M | 22.68M | 33.66M | 24.9M |
| Selling, General & Admin | 17.78M | 5.63M | 11.9M | 11.33M | 12.81M |
| Operating Expenses | 66.39M | 22.68M | 34.58M | 43.81M | 36.59M |
| Depreciation & Amortization | 801K | 1.06M | 1.17M | 1.18M | 1.13M |
| EBITDA | (51.93M) | (23.55M) | (32.97M) | (50.27M) | (37.31M) |
| EBITDA Margin | -183.4% | — | — | — | — |
| Operating Income | (39.31M) | (23.73M) | (35.75M) | (44.99M) | (37.71M) |
| Operating Margin | -138.8% | — | — | — | — |
| Interest Income | 3.39K | 64.83K | 373K | 777K | 776K |
| Interest Expense | 876.44K | 3.6M | 1.06M | 455K | 1.13M |
| Other Income / Expenses | (15.27M) | (4.48M) | 550K | (6.91M) | (1.86M) |
| Income Before Tax | (54.57M) | (28.21M) | (35.2M) | (51.9M) | (39.57M) |
| Pre-Tax Margin | -192.8% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.4M) | (28.21M) | (35.2M) | (51.9M) | (39.57M) |
| Net Margin | -93.2% | — | — | — | — |
| EPS (Basic) | (19.32) | (9.10) | (6.96) | (4.25) | (2.58) |
| EPS (Diluted) | (19.32) | (9.10) | (6.96) | (4.25) | (2.58) |
| 3.2M | 3.1M | 5.06M | 12.2M | 15.31M | |
| 3.2M | 3.1M | 5.06M | 12.2M | 15.31M |
ELTX Earnings Waterfall · TTM
NASDAQ:ELTX · Revenue to Net Income
Key Ratios
EPS$-2.36
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.9
P/S Ratio0.0
Analysis
$0 of revenue converted into -$40.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.36, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | |
| 8-K | Current report | Aug 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 17, 2026 |
How much revenue does ELTX generate?
Elicio Therapeutics, Inc. (ELTX) reported $0.00 of revenue in fiscal 2025.
Is ELTX profitable?
Elicio Therapeutics, Inc. (ELTX) reported -$39.57M of net income.
Continue the stock analysis
Jump to another research area for this company.